Popular Trials
Monoclonal Antibodies
REGN5459 + REGN5458 for Transplant-Ready Chronic Kidney Disease
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests the safety of two experimental drugs, REGN5459 and REGN5458, in kidney disease patients who need a transplant but have high antibody levels that make finding a donor difficult. The drugs work by lowering these antibodies to improve donor compatibility.
Calcineurin Inhibitor
Once-Daily vs Twice-Daily Tacrolimus for Kidney Transplant Recipients
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is testing whether a once-daily tacrolimus pill causes fewer side effects and is more convenient than the twice-daily tacrolimus pill, and whether patients' quality of life is better on the once-daily pill.
Stem Cell-Induced Immune Tolerance for Renal Disease
Recruiting1 awardPhase 1
Stanford, California
This trial tests if giving special cells from a kidney donor can help patients accept a new kidney without needing long-term medication. It targets patients receiving a kidney from a related donor. The treatment involves preparing the body and mixing donor and patient immune cells to prevent rejection.
Bone Marrow Aspiration for Kidney Transplant Rejection
Recruiting1 award3 criteria
Rochester, Minnesota
This trial is testing whether two different tests can show why patients who have had a kidney transplant and have developed antibodies against their donor are at a greater risk for their transplanted organ being rejected.
Hematopoietic Stem Cell Transplantation
Hematopoietic Cell Transplantation for Immune Tolerance in Kidney Transplant Recipients
Recruiting1 awardPhase 1
Palo Alto, California
This trial will test if patients with a functioning kidney transplant and a matching donor can discontinue immunosuppressive drugs while maintaining normal renal function.
Popular Filters
Trials for Chronic Kidney Disease Patients
Immunosuppressant
Immunosuppressants for Kidney Transplant
Recruiting1 award1 criteria
Vancouver, British Columbia
"This trial aims to investigate if continuing immunosuppressants after a failed kidney transplant for two years can lower the risk of the immune system attacking a new kidney. The study involves 96 patients at
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Behavioral Intervention
mHealth Messaging for Transplant Medication Adherence
Recruiting1 award
Baltimore, Maryland
"This trial aims to see if a mobile technology intervention can help young people who have had kidney or liver transplants to remember to take their medication on time. The intervention includes an electronic pillbox and text
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
Recruiting1 awardPhase 1
Los Angeles, California
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Behavioural Intervention
Screening Strategies for Coronary Artery Disease in Kidney Transplant Candidates
Recruiting1 award5 criteria
Washington, District of Columbia
This trial will test if eliminating regular use of non-invasive screening tests for CAD after waitlist activation is not worse than regular screening during wait-listing.
Trials for Kidney Failure Patients
Immunosuppressant
Immunosuppressants for Kidney Transplant
Recruiting1 award1 criteria
Vancouver, British Columbia
"This trial aims to investigate if continuing immunosuppressants after a failed kidney transplant for two years can lower the risk of the immune system attacking a new kidney. The study involves 96 patients at
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Behavioral Intervention
mHealth Messaging for Transplant Medication Adherence
Recruiting1 award
Baltimore, Maryland
"This trial aims to see if a mobile technology intervention can help young people who have had kidney or liver transplants to remember to take their medication on time. The intervention includes an electronic pillbox and text
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
Recruiting1 awardPhase 1
Los Angeles, California
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Behavioural Intervention
Screening Strategies for Coronary Artery Disease in Kidney Transplant Candidates
Recruiting1 award5 criteria
Washington, District of Columbia
This trial will test if eliminating regular use of non-invasive screening tests for CAD after waitlist activation is not worse than regular screening during wait-listing.
Phase 3 Trials
Virus Vaccine
Herpes Zoster Vaccine for Shingles
Recruiting2 awardsPhase 3
Toronto, Ontario
This trial evaluates how well a shingles vaccine works and its safety over several years after initial vaccination. It also looks at immune responses and safety after giving two more doses several years later. Previous studies demonstrated the vaccine's effectiveness for a few years after vaccination.
Virus Therapy
Janssen COVID-19 Vaccine Booster for Kidney Transplant Recipients
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing if one dose of the Janssen vaccine can provide enough immunity for people who have had kidney transplants and have already received two or three doses of another vaccine.
Virus Therapy
Anti-BKV Therapy for BK Virus Infection in Kidney Transplant Patients
Recruiting0 awardsPhase 2 & 3
Charlotte, North Carolina
This trial is testing AntiBKV, an IV treatment for reducing BKV virus levels in kidney transplant patients. The goal is to see if it can safely and effectively lower the virus and prevent kidney damage.
Trials With No Placebo
Immunosuppressant
Immunosuppressants for Kidney Transplant
Recruiting1 award1 criteria
Vancouver, British Columbia
"This trial aims to investigate if continuing immunosuppressants after a failed kidney transplant for two years can lower the risk of the immune system attacking a new kidney. The study involves 96 patients at
Lifestyle Intervention for Kidney Transplant Recipients
Recruiting1 award1 criteria
Kansas City, Kansas
This trial aims to study whether implementing a lifestyle intervention can help prevent weight gain in patients who have undergone kidney transplantation compared to those receiving standard medical care alone. The study will look at factors such as adherence
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Behavioral Intervention
mHealth Messaging for Transplant Medication Adherence
Recruiting1 award
Baltimore, Maryland
"This trial aims to see if a mobile technology intervention can help young people who have had kidney or liver transplants to remember to take their medication on time. The intervention includes an electronic pillbox and text
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
Recruiting1 awardPhase 1
Los Angeles, California
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.